Patents by Inventor Tim Marquart
Tim Marquart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090137802Abstract: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.Type: ApplicationFiled: January 28, 2009Publication date: May 28, 2009Inventors: Elfatih Elzein, Rao Kalla, Tim Marquart, Jeff Zablocki, Xiaofen Li
-
Patent number: 7521554Abstract: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.Type: GrantFiled: August 22, 2006Date of Patent: April 21, 2009Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Rao Kalla, Tim Marquart, Jeff Zablocki, Xiaofen Li
-
Patent number: 7449473Abstract: Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure: wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.Type: GrantFiled: October 26, 2004Date of Patent: November 11, 2008Assignee: CV Therapeutics, Inc.Inventors: Rao Kalla, Elfatih Elzein, Tim Marquart, Thao Perry, Xiaofen Li, Jeff Zablocki
-
Publication number: 20070191390Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.Type: ApplicationFiled: March 13, 2007Publication date: August 16, 2007Inventors: Jeff Zablocki, Elfatih Elzein, Tim Marquart
-
Patent number: 7208496Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.Type: GrantFiled: June 7, 2004Date of Patent: April 24, 2007Assignee: CV Therapeutics, Inc.Inventors: Jeff Zablocki, Elfatih Elzein, Tim Marquart
-
Publication number: 20060281921Abstract: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.Type: ApplicationFiled: August 22, 2006Publication date: December 14, 2006Inventors: Elfatih Elzein, Rao Kalla, Tim Marquart, Jeff Zablocki, Xiaofen Li
-
Patent number: 7125993Abstract: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, having the structure of Formula I or Formula II: by cyclizing a compound of the formula (3):Type: GrantFiled: November 21, 2003Date of Patent: October 24, 2006Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Rao Kalla, Tim Marquart, Jeff Zablocki, Xiaofen Li
-
Patent number: 7026321Abstract: Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.Type: GrantFiled: January 16, 2004Date of Patent: April 11, 2006Assignee: CV Therapeutics, Inc.Inventors: Robert Jiang, Tim Marquart, Jeff Zablocki, Elfatih Elzein, Venkata Palle, Prabha Ibrahim
-
Publication number: 20050119287Abstract: Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure: wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.Type: ApplicationFiled: October 26, 2004Publication date: June 2, 2005Inventors: Rao Kalla, Elfatih Elzein, Tim Marquart, Thao Perry, Xiaofen Li, Jeff Zablocki
-
Publication number: 20050049254Abstract: Disclosed are novel piperazine derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction.Type: ApplicationFiled: June 7, 2004Publication date: March 3, 2005Inventors: Jeff Zablocki, Elfatih Elzein, Tim Marquart
-
Patent number: 6852723Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.Type: GrantFiled: February 11, 2003Date of Patent: February 8, 2005Assignee: CV Therapeutics, Inc.Inventors: Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn, Tim Marquart, Prabha N. Ibrahim, Venkata P. Palle
-
Publication number: 20040186109Abstract: Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.Type: ApplicationFiled: January 16, 2004Publication date: September 23, 2004Inventors: Robert Jiang, Tim Marquart, Jeff Zablocki, Elfatih Elzein, Venkata Palle, Prabha Ibrahim
-
Publication number: 20040176399Abstract: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.Type: ApplicationFiled: November 21, 2003Publication date: September 9, 2004Inventors: Elfatih Elzein, Rao Kalla, Tim Marquart, Jeff Zablocki, Xiaofen Li
-
Patent number: 6677336Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.Type: GrantFiled: February 22, 2001Date of Patent: January 13, 2004Assignee: CV Therapeutics, Inc.Inventors: Jeff Zablocki, Elfatih Elzein, Grigory Nudelman, Tim Marquart, Brent K. Blackburn, Venkata P. Palle
-
Patent number: 6638970Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.Type: GrantFiled: February 22, 2001Date of Patent: October 28, 2003Assignee: CV Therapeutics, Inc.Inventors: Elfaith Elzein, Jeff Zablocki, Tim Marquart
-
Publication number: 20030176440Abstract: Novel compounds of the general formula: 1Type: ApplicationFiled: February 11, 2003Publication date: September 18, 2003Applicant: CV Therapeutics, Inc.Inventors: Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn, Tim Marquart, Prabha N. Ibrahim, Venkata P. Palle
-
Patent number: 6552023Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.Type: GrantFiled: February 22, 2001Date of Patent: April 22, 2003Assignee: CV Therapeutics, Inc.Inventors: Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn, Tim Marquart, Prabha N. Ibrahim, Venkata P. Palle
-
Publication number: 20020016463Abstract: Novel compounds of the general formula: 1Type: ApplicationFiled: February 22, 2001Publication date: February 7, 2002Inventors: Jeff Zablocki, Elfatih Elzein, Grigory Nudelman, Tim Marquart, Brent K. Blackburn, Venkata P. Palle
-
Publication number: 20010041704Abstract: Novel compounds of the general formula: 1Type: ApplicationFiled: February 22, 2001Publication date: November 15, 2001Inventors: Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn, Tim Marquart, Prabha N. Ibrahim, Venkata P. Palle
-
Publication number: 20010036961Abstract: Novel compounds of the general formula: 1Type: ApplicationFiled: February 22, 2001Publication date: November 1, 2001Inventors: Elfatih Elzein, Jeff Zablocki, Tim Marquart